Toripalimab (JS001 )

DRUG3 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., West China Hospital

Conditions

Hepatocellular CarcinomaUrinary Bladder NeoplasmsUrothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma RecurrentUrothelial Carcinoma of the Renal Pelvis and Ureter

Phase 1

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

TerminatedNCT03867370

Shanghai Junshi Bioscience Co., Ltd.Hepatocellular Carcinoma

Start: 2019-04-26End: 2023-08-08Updated: 2023-11-29

Phase 2

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

RecruitingNCT06823427

Mabwell (Shanghai) Bioscience Co., Ltd.Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter +1

Start: 2025-01-17End: 2027-06-30Target: 60Updated: 2025-03-21

HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC

Not yet recruitingNCT07608224

West China HospitalUrinary Bladder Neoplasms

Start: 2026-06-20End: 2030-12-31Target: 240Updated: 2026-05-27

Related Papers

Abstract 486: A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC)

Cancer Research2021-07-0119 citations